OOIR: Observatory of International Research

Papers

(The H4-Index of Journal of the European Academy of Dermatology and Venereology is 54. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-04-01 to 2024-04-01.)

Article	Citations
Cutaneous manifestations in COVID‐19: a first perspective	692
ETFAD/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children	216
Vascular skin symptoms in COVID‐19: a French observational study	188
Chilblain‐like lesions during COVID‐19 epidemic: a preliminary study on 63 patients	177
Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the european academy of dermatology and venereology (EADV)	165
Hidradenitis suppurativa: an update on epidemiology, phenotypes, diagnosis, pathogenesis, comorbidities and quality of life	160
Urticarial eruption in COVID‐19 infection	157
2020 European guideline on the management of syphilis	156
Onychomycosis: a review	143
Cutaneous findings following COVID‐19 vaccination: review of world literature and own experience	141
Cutaneous manifestations in COVID‐19: a new contribution	141
EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris – Part 1: treatment and monitoring recommendations	140
Acral cutaneous lesions in the time of COVID‐19	133
European guideline (EuroGuiDerm) on atopic eczema: part I – systemic therapy	117
A clinical, histopathological and laboratory study of 19 consecutive Italian paediatric patients with chilblain‐like lesions: lights and shadows on the relationship with COVID‐19 infection	107
A distinctive skin rash associated with coronavirus disease 2019?	106
COVID‐19 and cutaneous manifestations: a systematic review	99
Pooled safety analysis of baricitinib in adult patients with atopic dermatitis from 8 randomized clinical trials	99
Cutaneous manifestations in COVID‐19: the experiences of Barcelona and Rome	95
Cutaneous manifestations of SARS‐CoV‐2 infection: a clinical update	92
European Task Force on Atopic Dermatitis statement on severe acute respiratory syndrome coronavirus 2 (SARS‐Cov‐2) infection and atopic dermatitis	89
Pityriasis rosea as a cutaneous manifestation of COVID‐19 infection	87
EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris – Part 2: specific clinical and comorbid situations	86
Clinical and biological impact of the exposome on the skin	86
Acute urticaria with pyrexia as the first manifestations of a COVID‐19 infection	85

Comment on ‘Cutaneous manifestations in COVID‐19: a first perspective’ by Recalcati S	81
European Guidelines (S3) on diagnosis and management of mucous membrane pemphigoid, initiated by the European Academy of Dermatology and Venereology – Part II	81
Dermatologists and SARS‐CoV‐2: the impact of the pandemic on daily practice	80
European S1 guidelines on the management of lichen planus: a cooperation of the European Dermatology Forum with the European Academy of Dermatology and Venereology	77
Photoprotection according to skin phototype and dermatoses: practical recommendations from an expert panel	77
Comment on: Cutaneous manifestations in COVID‐19: a first perspective. Safety concerns of clinical images and skin biopsies	74
2021 European guideline on the management of Mycoplasma genitalium infections	73
European guideline (EuroGuiDerm) on atopic eczema – part II: non‐systemic treatments and treatment recommendations for special AE patient populations	70
The first dose of COVID‐19 vaccine may trigger pemphigus and bullous pemphigoid flares: is the second dose therefore contraindicated?	66
Dupilumab therapy of atopic dermatitis of the elderly: a multicentre, real‐life study	65
Comparative efficacy and safety of systemic therapies used in moderate‐to‐severe atopic dermatitis: a systematic literature review and network meta‐analysis	65
Erythema multiforme and Kawasaki disease associated with COVID‐19 infection in children	64
Lichen planus arising after COVID‐19 vaccination	64
2019 IUSTI‐Europe guideline for the management of anogenital warts	64
Personal protective equipment induced facial dermatoses in healthcare workers managing Coronavirus disease 2019	63
Skin manifestations of the BNT162b2 mRNA COVID‐19 vaccine in healthcare workers. ‘COVID‐arm’: a clinical and histological characterization	62
3D wide‐field multispectral photoacoustic imaging of human melanomas in vivo: a pilot study	62
Skin reactions to non‐glove personal protective equipment: an emerging issue in the COVID‐19 pandemic	61
UpdatedS2K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (EADV)	61
Psoriasis exacerbation after COVID‐19 vaccination: a report of 14 cases from a single centre	60
Delayed melanoma diagnosis in the COVID‐19 era: increased breslow thickness in primary melanomas seen after the COVID‐19 lockdown	59
European guidelines (S3) on diagnosis and management of mucous membrane pemphigoid, initiated by the European Academy of Dermatology and Venereology – Part I	59
Secukinumab demonstrates high efficacy and a favourable safety profile in paediatric patients with severe chronic plaque psoriasis: 52‐week results from a Phase 3 double‐blind randomized, controlled t	59
Line‐field confocal optical coherence tomography of basal cell carcinoma: a descriptive study	57
Transient cutaneous manifestations after administration of Pfizer‐BioNTech COVID‐19 Vaccine: an Italian single‐centre case series	57
Common causes of hair loss – clinical manifestations, trichoscopy and therapy	56
Cutaneous manifestations in SARS‐CoV‐2 infection (COVID‐19): a French experience and a systematic review of the literature	55
Emerging antifungal treatment failure of dermatophytosis in Europe: take care or it may become endemic	54
SARS‐CoV‐2 infection presenting as a febrile rash	54
Prevalence of most common skin diseases in Europe: a population‐based study	54